All AbMole products are for research use only, cannot be used for human consumption.
Glecaprevir is a hepatitis C virus (HCV) nonstructural (NS) protein 3/4A protease inhibitor that targets the the viral RNA replication. It displays IC50 values ranging from 3.5 to 11.3 nM for clinical isolates of HCV genotypes 1a, 1b, 2a, 2b, 3a, 4a, 5a, and 6a.
| Molecular Weight | 838.87 |
| Formula | C38H46F4N6O9S |
| CAS Number | 1365970-03-1 |
| Solubility (25°C) | DMSO 100 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
[2] No authors listed. Aust Prescr. Glecaprevir/pibrentasvir for hepatitis C
[3] No authors listed. Glecaprevir
[5] Yvette N Lamb. Drugs. Glecaprevir/Pibrentasvir: First Global Approval
| Related HCV Protease Products |
|---|
| Telaprevir
Telaprevir (VX-950) is a novel hepatitis C virus (HCV) NS3-4A protease inhibitor with IC50 of < 0.2 μM. |
| BMS-790052
BMS-790052 (Daclatasvir) is a first-in-class, nonstructural protein 5A (NS5A) replication complex inhibitor with an EC50 of 9-50 pM. |
| (R)-Nepicastat hydrochloride
(R)-Nepicastat hydrochloride, the R-enantiomer of Nepicastat hydrochloride, is a potent and selective inhibitor with IC50 of 25.1 nM and 18.3 nM for bovine and human dopamine-β-hydroxylase, with negligible affinity for twelve other enzymes and thirteen neurotransmitter receptors. |
| Elbasvir
Elbasvir (MK-8742) is a hepatitis C virus nonstructural protein 5A (HCV NS5A) replication complex inhibitor, with EC50s of 4, 3 and 3 nM against genotype 1a, 1b, and 2a, respectively. |
| Dasabuvir (ABT-333)
ABT-333 is a nonnucleoside NS5B polymerase inhibitor for the treatment of HCV infection. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
